Global Deep Vein Thrombosis Market 2027: Top Key Players Sandoz Inc. Teva Pharmaceuticals USA, Inc. Sanofi-Aventis U.S. LLC, Pfizer Inc. Baxter International Inc., West-Ward Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc.

Deep vein thrombosis (DVT) is serious condition that occur when clots forms in the deep veins of the body. The most dangerous complication of deep vein thrombosis is pulmonary embolism (PE), which can either be asymptomatic or symptomatic. Surgery and pregnancy are the major risk factors associated with deep vein thrombosis. Pregnancy increase hormone level and slower blood flow lead to expansion of uterus and restrict blood flowing back from lower extremities responsible for deep vein thrombosis. Diagnosis of deep vein thrombosis can be made with blood test such as D-dimer test and imaging test such as Doppler ultrasound (Duplex), contrast venogram, magnetic resonance imaging (MRI) and computer tomography (CT). There are four type of treatments for deep vein thrombosis include anticoagulant, thrombolytic therapy, IVC filters (Vein Filters) and Stents.

Request For Sample @ https://bit.ly/2IO4DwJ

hAnticoagulant such as unfractionated heparin, low molecular weight heparin (enoxaparin/ Lovenox, dalteparin/Fragmin, or tinzaparin/Innohep, fondaparinux/Arixtra or desirudin/Iprivask), warfarin (Coumadin and Jantoven) are the primary treatment deep vein thrombosis. Thrombolytic therapy such as tissue plasminogen activator agents (tPA) can helps to dissolve blood clot. IVC filters (Vein Filters) also known as “Greenfield filters” is umbrella shaped device that placed into large vein which traps blood clot and prevent deep vein thrombosis and pulmonary embolism. Stents are metal meshwork tubes that are placed into vein to keep them open.

Almost one-half million patients are hospitalized for venous thromboembolism (consist of deep vein thrombosis and pulmonary embolism) each year in United State. In Europe, there are 544,000 venous thromboembolism related death every year. Venous thromboembolism can cause significant global economic burden. Various diagnostic test and treatment, prolonged hospital stay and follow-up care can be extremely costly for instance estimated medical cost for venous thromboembolism in the U.S is $5-10 billion per year. In U.K venous thromboembolism related cost is 750 million per year. In Australia venous thromboembolism related cost are estimated 1.72 billion a year. On June 2017, U.S. FDA (Food and Drug Administration) approved betrixaban (Portola) for the adult with venous thromboembolism (VTE). Pentasaccharides such XARELTO are novel anticoagulant may preferred over standard therapy due to few drug interaction and no need to frequent monitoring or re-dosing.

Request For Table Of Content (TOC) @ https://bit.ly/2IO4DwJ

Prominent key players operating deep vein thrombosis (DVT) market are Sandoz Inc. Teva Pharmaceuticals USA, Inc. Sanofi-Aventis U.S. LLC, Pfizer Inc. Baxter International Inc., West-Ward Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc. and others.

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products.

Contact Us:
Mr. John Smith
InsightAce Analytic Pvt. Ltd.
Pune, Maharashtra, India
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: https://www.insightaceanalytic.com
Follow Us on LinkedIn @ https://bit.ly/2tBXsgS
Follow Us On Facebook @ https://bit.ly/2H9jnDZ

This release was published on openPR.